Clinical Trial Update: Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating whether naloxone can reduce postictal central respiratory dysfunction in epilepsy patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Naloxone (Naloxone)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Epilepsy | Phase 3 | Status: COMPLETED